News

WASHINGTON, October 21, 2004 (LifeSiteNews.com) – The United States Conference of Catholic Bishops (USCCB) this week launches a nationwide two-week ad campaign highlighting the issue of stem cell research. The ads draw a clear distinction between embryonic stem cell research, which requires the destruction of human life at the embryonic stage, and adult stem cell research.

“Stem cell research is one of the most important moral issues of our day, but it is also one of the most distorted,” said Cathy Cleaver Ruse, Esq., Director of Planning and Information for the USCCB's Secretariat for Pro-Life Activities. “In the public debate, embryo-destructive research has been greatly hyped, while the proven results of ethical adult stem cell research are very nearly ignored.”

“Our ads explain that adult stem cell research is already helping people with heart disease, spinal cord injury, Parkinson's and many other diseases. Embryonic stem cells, on the other hand, have not helped one single human patient, and they come with a hefty price tag: the deliberate destruction of human life,” Ruse said. “As our ads state: science does not have to kill in order to cure.”

The ads will appear in USA Today, The Washington Times and the National Catholic Reporter. The ads have also gone to dioceses nationwide for use in local publications.

jhw

Comments

Commenting Guidelines
LifeSiteNews welcomes thoughtful, respectful comments that add useful information or insights. Demeaning, hostile or propagandistic comments, and streams not related to the storyline, will be removed.

LSN commenting is not for frequent personal blogging, on-going debates or theological or other disputes between commenters.

Multiple comments from one person under a story are discouraged (suggested maximum of three). Capitalized sentences or comments will be removed (Internet shouting).

LifeSiteNews gives priority to pro-life, pro-family commenters and reserves the right to edit or remove comments.

Comments under LifeSiteNews stories do not necessarily represent the views of LifeSiteNews.

0 Comments

    Loading...